[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hpv-16":3},{"name":4,"total":5,"recruiting":5,"trials":6},"HPV-16",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07172256","CUE-101with Pembrolizumab for LA-HPV+HNSCCs",[11],"Phase 2","RECRUITING","2026-08-26T02:17:34.833510Z","2026-05-05T02:43:27.601527Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05307939","A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)",[11],"2026-08-26T02:19:22.562392Z","2026-05-05T02:43:28.812774Z"]